Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06082960 · ClinicalTrials.gov registry record · Phase 1

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Gilead Sciences.

Active
Registry status
Phase 1
Development phase
45
Enrollment target
6
Study locations

NCT06082960 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 45 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06082960, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Gilead Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
6
Study locations

Study Summary

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors

Conditions Studied

Solid Tumors

Interventions

  • DRUG Zimberelimab
  • DRUG GS-9911

Study Locations (6)

Texas

  • NEXT Oncology - San Antonio
  • South Texas Accelerated Research Therapeutics, LLC - San Antonio

Connecticut

  • Smilow Cancer Hospital Phase 1 Unit - New Haven

Tennessee

  • SCRI Oncology Partners - Nashville

Victoria

  • Peter MacCallum Cancer Centre - Melbourne

Other

  • University Health Network, Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2023-10-09
Est. Completion 2026-11
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06082960

The ClinicalTrials.gov registry entry for NCT06082960 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.

NCT06082960 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, Connecticut, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06082960 about?

NCT06082960 is a clinical study titled "Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors". The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * ...

What is the current status of trial NCT06082960?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-10-09. Estimated completion is 2026-11.

What conditions does trial NCT06082960 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT06082960?

The interventions under investigation include: Zimberelimab (DRUG), GS-9911 (DRUG).

Who is sponsoring clinical trial NCT06082960?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06082960 being conducted?

This trial has 6 study locations across Connecticut, Tennessee, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.